Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (NCT03917082)
LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk of breast cancer; as determined by histopathologic criteria and confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this population, and will not compromise the expected excellent breast cancer specific outcomes for this population.
Who can join: Review the eligibility criteria below.
Location: BC Cancer — Vancouver, British Columbia
Age range: 51 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- BC Cancer — Vancouver, British Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer Female
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — Tampa, Florida
- Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial — Phoenix, Arizona
- Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer — Charlottesville, Virginia
- Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women — Aurora, Colorado
- Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes — Detroit, Michigan
- Robotic vs. Open NSM for Early Stage Breast Cancer — Irvine, California
Explore by condition: All Breast Cancer Female clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.